# B-Receptor Signaling in Cardiomyopathy

> **NCT01135849** · — · COMPLETED · sponsor: **Daniel Bernstein** · enrollment: 99 (actual)

## Conditions studied

- Carcinomas
- Amyloidosis
- Anal Cancer
- Anemia
- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Transitional Cell Carcinoma of Bladder
- Bone Marrow Transplant Failure
- Bone Cancer
- Cancer of Brain and Nervous System
- Breast Cancer
- Carcinoma of the Large Intestine
- Endocrine Cancer
- Esophageal Cancer
- Eye Cancer
- Gall Bladder Cancer
- Gastric (Stomach) Cancer
- Gastrooesophageal Cancer
- Gastrointestinal Stromal Tumor (GIST)
- Gynecologic Cancers
- Head and Neck Cancers
- Hepatobiliary Neoplasm
- Kidney (Renal Cell) Cancer
- Leukemia
- Lung Cancer
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Mesothelioma
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Neuroendocrine Tumors
- Myeloproliferative Disorders
- Pancreatic Cancer
- Prostate Cancer
- Skin Cancer
- Soft Tissue Sarcoma
- Testicular Cancer
- Thymus Cancer
- Thyroid Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01135849
- **Lead sponsor:** Daniel Bernstein
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2015-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01135849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01135849, "B-Receptor Signaling in Cardiomyopathy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01135849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*